Systemic treatment strategy for metastatic colorectal cancer in 2020, emphasis on new molecules

02/2021

Doc. MUDr. David Vrána, Ph.D.

Komplexní onkologické centrum, Nemocnice Nový Jičín

SUMMARY

The treatment of the metastatic colorectal cancer is unfortunately mostly palliative. There are new molecules which have entered the treatment algorithm of the colorectal cancer. From the immunotherapy pembrolizumab, nivolumab or combination of nivolumab with ipilimumab have been approved by the Food and Drug Administration (FDA) for the previously treated colorectal cancer with mismatch repair deficiency / high microsatellite instability (dMMR/MSI-H) and also pembrolizumab has gained approval FDA in the first line palliative treatment. In the Czech Republic unfortunately there are all these molecules in the diagnosis of colorectal cancer without registration and without reimbursement. At the same time there is new combination of cetuximab with encorafenib in previously treated patients with BRAF V600E mutation unfortunately without reimbursement.

Key words

metastatic colorectal cancer, immunotherapy, pembrolizumab, cetuximab, nivolumab, encorafenib, binimetinib